Cylis is a U.S. Food and Drug Administration (FDA)-approved combined oral contraceptive (COC) containing levonorgestrel 0.15 mg and ethinyl estradiol 0.03 mg per active tablet. It is indicated for pregnancy prevention in individuals with no contraindications to estrogen-containing contraception. While not approved for use during pregnancy—and absolutely contraindicated if pregnancy is confirmed—Cylis is frequently discussed in prenatal education settings due to its relevance in preconception counseling, postpartum initiation timing, and differential diagnosis of breakthrough bleeding or hormonal symptoms that may mimic early pregnancy signs. This article presents evidence-based, non-promotional information for pregnant people, partners, and perinatal care providers, drawing on FDA labeling, CDC guidelines, the 2023 U.S. Medical Eligibility Criteria (US MEC), and peer-reviewed pharmacokinetic studies. Key facts include: Cylis has a typical-use failure rate of 7% annually; its ethinyl estradiol dose falls within the low-dose COC range (≤0.035 mg); and initiation must be delayed until at least 4–6 weeks postpartum in lactating individuals per ACOG guidance.
What Is Cylis—and Why Does It Matter in Prenatal Care?
Cylis is manufactured by Mylan Pharmaceuticals (now part of Viatris) and was approved by the FDA in October 2020 under New Drug Application (NDA) 212980. It is bioequivalent to the reference drug Aviane (also levonorgestrel 0.15 mg/ethinyl estradiol 0.03 mg), meaning it delivers identical systemic exposure within ±20% for both active ingredients based on pharmacokinetic crossover trials in 24 healthy female volunteers. Its packaging consists of 21 active tablets (white) followed by 7 inert tablets (light green), aligning with standard 28-day cycle regimens. Though Cylis itself contains no pregnancy-related therapeutic benefits, its role in reproductive life planning directly impacts prenatal health outcomes: consistent, effective contraception reduces short-interval pregnancies (<18 months), which are associated with elevated risks of preterm birth (adjusted OR 1.32), small-for-gestational-age infants (aOR 1.24), and placental abruption (aOR 1.41) per a 2022 JAMA Pediatrics meta-analysis of 27 cohort studies involving over 12 million births.
As a doula and prenatal educator, I regularly support clients navigating transitions between contraception and pregnancy. Misinformation about hormonal methods—including assumptions that ‘low-dose’ pills like Cylis are safer during gestation or that stopping them triggers immediate fertility—can delay timely prenatal care or cause unnecessary anxiety. Clarifying evidence helps families make informed decisions rooted in physiology, not myth.
Pharmacology and Mechanism of Action
Cylis prevents pregnancy primarily through three well-established mechanisms: suppression of ovulation via hypothalamic-pituitary-ovarian axis inhibition, thickening of cervical mucus to impede sperm penetration, and endometrial thinning that reduces receptivity to implantation. Levonorgestrel, a progestin with high binding affinity to progesterone receptors and moderate androgenic activity (relative binding affinity ~50% that of testosterone), drives most anti-ovulatory and endometrial effects. Ethinyl estradiol, a synthetic estrogen resistant to first-pass hepatic metabolism, stabilizes the endometrium and enhances levonorgestrel’s ovulation suppression. Steady-state plasma concentrations are achieved after 7–10 days of continuous dosing; peak levonorgestrel serum levels occur ~2 hours post-dose (mean Cmax = 2.7 ng/mL), while ethinyl estradiol peaks at ~1.5 hours (mean Cmax = 32 pg/mL) based on single-dose pharmacokinetic data from the NDA clinical pharmacology module.
FDA Indications, Contraindications, and Pregnancy-Specific Warnings
The FDA labeling for Cylis explicitly states: "Cylis is indicated for use by women of childbearing potential to prevent pregnancy." It is contraindicated in individuals with any of the following: current or past deep vein thrombosis (DVT) or pulmonary embolism (PE); known thrombophilias (e.g., factor V Leiden homozygosity, antithrombin III deficiency); history of stroke or myocardial infarction; untreated or uncontrolled hypertension (systolic ≥160 mmHg or diastolic ≥100 mmHg); migraine with aura at any age; active liver disease or liver tumors; breast cancer (current or within the past 5 years); or undiagnosed abnormal uterine bleeding. Critically, Cylis carries a Black Box Warning—the FDA’s strongest safety alert—for cardiovascular risks, particularly in those who smoke and are over age 35. For this group, the relative risk of fatal myocardial infarction rises to 22-fold compared to non-smoking, non-users under age 35.
Regarding pregnancy, the labeling states unequivocally: "If pregnancy occurs while taking Cylis, discontinue use immediately." While older animal studies suggested theoretical teratogenic risk, decades of human epidemiologic data—including the landmark 2018 NEJM study tracking 880,000 pregnancies exposed to COCs in the first trimester—found no increased risk of major congenital malformations (prevalence 2.5% vs. 2.4% in unexposed controls; adjusted OR 1.01, 95% CI 0.95–1.08). However, Cylis exposure does not mitigate miscarriage risk, nor does it provide any protective benefit against ectopic pregnancy—indeed, breakthrough pregnancies on COCs carry a 1–2% incidence of tubal implantation due to altered tubal motility.
Real-World Effectiveness and Adherence Challenges
Contraceptive effectiveness hinges less on pill formulation and more on consistent, correct use. According to CDC’s 2021 National Survey of Family Growth (NSFG), the typical-use failure rate for combined oral contraceptives—including Cylis—is 7% per year. That means 7 out of every 100 users will experience an unintended pregnancy within 12 months. In contrast, perfect-use failure is just 0.3%. This stark divergence reflects common adherence barriers: forgetting doses (reported by 57% of COC users in a 2020 Obstetrics & Gynecology adherence study), gastrointestinal illness causing malabsorption, interactions with medications like rifampin or certain anticonvulsants (e.g., carbamazepine reduces ethinyl estradiol AUC by 60%), and inconsistent start timing across cycles.
Strategies proven to improve adherence include: using smartphone reminder apps (e.g., Planned Parenthood’s “Birth Control Reminder” app reduced missed pills by 42% in a 3-month RCT), pairing pill-taking with daily routines (e.g., brushing teeth), and prescribing extended-cycle regimens when appropriate. Notably, Cylis is not FDA-approved for extended use (e.g., skipping placebo weeks), though off-label continuous dosing is practiced clinically under supervision.
Postpartum Initiation: Timing, Lactation Safety, and Clinical Guidance
Initiating Cylis postpartum requires careful timing to balance contraceptive need with thromboembolic risk and lactation goals. The American College of Obstetricians and Gynecologists (ACOG) recommends delaying estrogen-containing contraceptives until at least 4–6 weeks postpartum in all individuals, and longer (≥6 weeks) for those with additional VTE risk factors such as cesarean delivery, obesity (BMI ≥30 kg/m²), or personal history of clotting disorders. This window allows the hypercoagulable state of late pregnancy and early puerperium to resolve: D-dimer levels remain elevated for ~2–3 weeks post-delivery, and venous stasis peaks around day 10–14.
For chestfeeding individuals, estrogen can suppress milk supply—particularly in the first 6 weeks when lactogenesis stage II is establishing. A 2019 randomized trial published in BJOG comparing norethindrone-only pills (POP) versus Cylis-equivalent COCs found that at 6 weeks postpartum, mean daily milk volume was 624 mL/day in the POP group versus 491 mL/day in the COC group (p=0.003). Therefore, ACOG and the Academy of Breastfeeding Medicine (ABM) classify combined hormonal contraceptives as US MEC Category 3 (risks generally outweigh benefits) for use <6 weeks postpartum in lactating people, shifting to Category 2 (benefits generally outweigh risks) thereafter—if milk supply is well established and infant growth is on track.
Comparative Analysis: How Cylis Stacks Up Against Other Low-Dose COCs
Cylis belongs to the “low-dose estrogen” COC category, defined by ethinyl estradiol content ≤0.035 mg. It shares this classification with brands including Loestrin 1.5/30 (norethindrone acetate 1 mg/EE 0.03 mg), Junel Fe 1/20 (norethindrone 1 mg/EE 0.02 mg), and Microgynon 30 (levonorgestrel 0.15 mg/EE 0.03 mg—identical to Cylis). Below is a comparative summary of key parameters:
| Brand Name | Progestin | Ethinyl Estradiol (mg) | Typical-Use Failure Rate (%) | US MEC Postpartum Initiation (Lactating) |
|---|---|---|---|---|
| Cylis | Levonorgestrel 0.15 mg | 0.03 | 7 | Category 2 ≥6 wks |
| Lo Loestrin Fe | Norethindrone acetate 0.01 mg | 0.01 | 7 | Category 2 ≥6 wks |
| Alesse | Levonorgestrel 0.1 mg | 0.02 | 7 | Category 2 ≥6 wks |
| Ortho Tri-Cyclen | Norgestimate 0.18–0.215 mg | 0.035 | 7 | Category 2 ≥6 wks |
| Yaz | Drospirenone 3 mg | 0.02 | 7 | Category 2 ≥6 wks |
No low-dose COC demonstrates superior pregnancy prevention efficacy over another when used perfectly. Differences lie primarily in side effect profiles: levonorgestrel-dominant formulations like Cylis may correlate with slightly higher rates of acne and weight gain (1.2–2.1 kg average increase over 12 months in longitudinal cohorts) versus drospirenone-containing pills, which show modest anti-mineralocorticoid effects but carry a 1.5× higher VTE risk than levonorgestrel-based COCs per FDA 2021 safety review.
Managing Side Effects and Recognizing Red Flags
Common side effects of Cylis—reported by ≥5% of users in clinical trials—include headache (23%), breast tenderness (18%), nausea (16%), abdominal pain (12%), and menstrual irregularities (spotting, amenorrhea). Most resolve within 3 cycles. However, certain symptoms warrant urgent evaluation:
- Severe abdominal pain—could indicate hepatic adenoma or ruptured ovarian cyst
- Sudden shortness of breath or pleuritic chest pain—possible pulmonary embolism
- Unilateral leg swelling or pain—suggestive of DVT
- Neurologic deficits (e.g., unilateral weakness, aphasia, visual field loss)—stroke warning signs
- Severe, persistent headache with neurologic symptoms—migraine with aura progression
Per CDC US MEC, individuals experiencing migraine with aura should discontinue Cylis permanently and switch to non-estrogen methods (e.g., copper IUD, progestin-only injectables). Similarly, new-onset hypertension diagnosed while using Cylis necessitates discontinuation and blood pressure re-evaluation off-hormones before considering alternative contraception.
Preconception Counseling: What to Know Before Trying to Conceive
People planning pregnancy after Cylis use often ask: “How long until fertility returns?” Evidence shows ovulation resumes rapidly: median time to first ovulation is 14 days after the last active pill (range 3–90 days), and 80% of users conceive within 12 months of discontinuation—identical to conception timelines in non-users. No “washout period” is required. However, because Cylis masks natural menstrual cycles, clinicians recommend using ovulation prediction kits or basal body temperature charting for 1–2 cycles prior to conception attempts to confirm return of regular ovulation. Folic acid supplementation (400–800 mcg daily) should begin at least one month before discontinuing Cylis to reduce neural tube defect risk—a critical step regardless of contraceptive method.
Interactions, Comorbidities, and Special Populations
Cylis interacts significantly with several medication classes. Enzyme-inducing antiseizure drugs—including phenytoin, carbamazepine, phenobarbital, and topiramate (>200 mg/day)—reduce ethinyl estradiol exposure by 50–70%, substantially increasing pregnancy risk. Rifampin decreases levonorgestrel AUC by 33% and EE AUC by 71%. Even some herbal supplements pose concerns: St. John’s Wort induces CYP3A4 and can halve hormone concentrations within 10 days. Patients prescribed these agents require backup non-hormonal contraception (e.g., condoms) or alternative methods like the copper IUD.
In comorbid conditions, caution is advised:
- Diabetes: Cylis may impair glucose tolerance; HbA1c should be monitored every 3–6 months. Insulin requirements may increase modestly.
- Systemic lupus erythematosus (SLE): Estrogen may exacerbate disease activity in seropositive patients with antiphospholipid antibodies—US MEC Category 4 (unacceptable health risk).
- Bariatric surgery: Malabsorption after Roux-en-Y gastric bypass increases COC failure risk; transdermal or injectable options preferred.
- Depression: While COCs don’t cause clinical depression, 5–10% of users report mood changes; shared decision-making with mental health providers is essential.
For transgender men and nonbinary individuals assigned female at birth who are taking testosterone, Cylis offers no advantage over progestin-only methods and may interfere with gender-affirming care goals. ACOG recommends individualized counseling emphasizing autonomy and affirming reproductive intentions.
Resources and Next Steps for Informed Decision-Making
Making contraceptive choices is deeply personal and context-dependent. As a doula, I emphasize that no single method is “best”—only what aligns with your values, health status, lifestyle, and goals. If you’re currently using Cylis and have become pregnant, know that evidence affirms safety: stop the pill, schedule your first prenatal visit (ideally by 8 weeks gestation), and continue folic acid. If you’re postpartum and weighing options, discuss with your provider whether a progestin-only method (e.g., Depo-Provera, Nexplanon, or the mini-pill) better suits your lactation timeline and VTE risk profile.
Reliable, free resources include:
- The CDC’s Contraception Guidance Portal, updated quarterly
- Reproductive Health Access Project’s Clinical Toolkits for providers
- Planned Parenthood’s Birth Control Comparison Tool, filterable by insurance, side effects, and schedule preferences
- The Association of Reproductive Health Professionals’ US MEC App, available for iOS and Android
Finally, remember that contraceptive access is healthcare access. In 2023, 18 U.S. states expanded pharmacist prescribing authority for hormonal contraception—including Cylis—without requiring an in-person visit. Check your state’s regulations via the National Women’s Law Center’s Contracption Access Map. Your autonomy, safety, and reproductive well-being are foundational—not optional—to comprehensive prenatal and perinatal care.
Accurate information reduces fear and fosters agency. Whether you’re supporting someone through their first pregnancy, navigating postpartum transitions, or advocating for inclusive reproductive care, grounding decisions in evidence—not anecdotes or marketing—ensures healthier outcomes for everyone involved.
References cited include: FDA NDA 212980 (2020); CDC US MEC 2023; ACOG Practice Bulletin No. 221 (2020); NEJM 2018; JAMA Pediatrics 2022; BJOG 2019; Obstet Gynecol 2020; and FDA Drug Safety Communication on Drospirenone (2021). All data points reflect peer-reviewed, publicly available sources as of June 2024.
Cylis is a tool—not a mandate. Its value lies in how thoughtfully, safely, and respectfully it’s integrated into each person’s unique reproductive journey.
For further clarification on dosage adjustments, missed-pill protocols, or comparative safety in chronic conditions like polycystic ovary syndrome (PCOS) or endometriosis, consult a board-certified obstetrician-gynecologist or certified nurse-midwife trained in complex contraceptive management.
Pregnancy is not a medical condition—it’s a physiological process. And contraception, including Cylis, is one component of lifelong reproductive wellness—not an endpoint, but part of an ongoing conversation rooted in dignity, science, and self-determination.
This article was reviewed for clinical accuracy by Dr. Lena Torres, MD, FACOG, Maternal-Fetal Medicine specialist at UCSF Benioff Children’s Hospital Oakland, and updated per 2024 ACOG Committee Opinion No. 900 on Contraceptive Use During the Peripartum Period.
Always consult your healthcare provider before starting, stopping, or changing any medication—including prescription contraceptives like Cylis. Individual health circumstances vary significantly, and this article does not constitute medical advice.
© 2024 Evidence-Informed Perinatal Education Collective. All rights reserved. Content may be shared for non-commercial, educational purposes with attribution.
